Loading…
← CockpitCompetitor Analysis › 688526.SS Wuhan Keqian Biology Co. Ltd. Class AOpen in the cockpit ↗

Wuhan Keqian Biology Co. Ltd. Class A688526.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum neutral 57
Mkt cap
$780M
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$2.15M
20-day average traded
Fwd P/E
19.4×
forward earnings
ROIC−WACC
-1.8 pp
WACC 9.7%
Hurdle
+5 pp
Req g minus delivered
Next earnings
153 days
20 Apr 2027
Close · CNYCN¥11.20
1D-1.1%
1W-2.4%
1M-7.0%
3M-14.6%
6M-23.9%
YTD-26.6%
1Y-29.8%
ATR %2.5%
52w lowhigh37.1% off high

What Wuhan Keqian Biology does

Employees: 950

Wuhan Keqian Biology at a glance

Size Wuhan Keqian Biology (688526.SS) is a China Health Care company (Biotechnology) with a market value of $780M, the 2645th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.20 on 18 Nov 2026.

Performance Over six months the shares fell 23.9%, against -13.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.

Growth Revenue fell 22.2% over the last twelve months (peer median +16.0%); the operating margin is 19.9% (peer median -107.8%).

Valuation It trades at 19.4× forward earnings against a peer median of 33.9× (cheapest of 5).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.8 points below its cost of capital (9.7% WACC).

Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 87688526.SS 78
Six months, rebased to 100: Wuhan Keqian Biology against the median of its 20 peers (local-currency closes).

Wuhan Keqian Biology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥787MCN¥946MCN¥938MCN¥1.06BCN¥997M
Revenue growth—+1%-11%+6%—
Gross profitCN¥549MCN¥613MCN¥579MCN¥738MCN¥709M
EBITDAn/aCN¥480MCN¥418MCN¥469MCN¥468M
Net incomeCN¥227MCN¥419MCN¥382MCN¥396MCN¥410M
Free cash flowCN¥272MCN¥423MCN¥326MCN¥494MCN¥377M
Capital expenditureCN¥127MCN¥124MCN¥107MCN¥105MCN¥103M
Total debtCN¥38.1MCN¥6.68MCN¥39.0MCN¥327MCN¥328M

Quarterly statements and history in the cockpit →

Wuhan Keqian Biology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-20%0%GLUESNDX9887IVAMGTXAURA002038OXB301333ATTOSLDBVSTM4587300841688526.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Wuhan Keqian Biology is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%50×100×150×30133345872160300841688526.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Wuhan Keqian Biology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002038301333301520300841688526.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Wuhan Keqian Biology is the large dot.

Wuhan Keqian Biology competitors and peer comparison

How Wuhan Keqian Biology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Wuhan Keqian Biology against its 20 peers (data as of 18 Nov 2026)
Measure688526.SSPeer medianRank in peer set
1-month return-7.0%-7.1%11th highest of 21
6-month return-23.9%-13.9%7th lowest of 19
Distance from 52-week high-37.1%-45.5%4th highest of 21
Revenue growth (TTM)-22.2%+16.0%4th lowest of 16
Operating margin19.9%-107.8%3rd highest of 18
Forward P/E19.4×33.9×cheapest of 5
Growth the price implies (Req g, 7 yrs)7.8%13.3%2nd least demanding of 5
Growth delivered (Del g)+2.4%+7.1%3rd highest of 5
Hurdle (Req g minus delivered)+5.4 pp+6.2 pp2nd least demanding of 5
ROIC minus cost of capital-1.8 pp-11.1 pp3rd highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%19.4×7.8%+2.4%
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%n/an/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%n/an/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%n/an/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%n/an/an/a
MeiraGTx MGTXUnited States$813M-13%+1,366%44%n/an/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%n/a-13.5%-10.9%
Apnimed APMDUnited States$726Mn/a+380%-140%n/an/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%n/an/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%37.9×17.3%+11.8%
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%n/an/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Verastem VSTMUnited States$866M+66%+650%-194%n/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%n/an/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%29.9×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%n/a44.8%+14.7%
Kura Oncology KURAUnited States$674M-29%-24%-394%n/an/an/a
GNI 2160.TJapan$903M-25%+44%-21%143.0×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%21.6×9.2%+2.3%

Questions

Which companies are Wuhan Keqian Biology's closest peers?
The cockpit's peer set: Monte Rosa Therapeutics (GLUE), Syndax Pharmaceuticals (SNDX), Nanjing Leads Biolabs (9887.HK), Inventiva (IVA.PA), MeiraGTx (MGTX), Aura Biosciences (AURA), Beijing SL Pharmaceutical (002038.SZ), Apnimed (APMD).
Is Wuhan Keqian Biology expensive compared with its peers?
On forward p/e it trades at 19.4× against a peer median of 33.9×, cheapest of 5 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Wuhan Keqian Biology stock performed?
Over six months to 18 Nov 2026 the shares returned -23.9% against -13.9% for the median peer; over one year -29.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.